Our team is developing measurement tools that feed into structured analytical data models. We are focused on neurodegenerative diseases starting with Multiple Sclerosis (MS).
Location: United States
Employees: 11-50
Total raised: $121.6M
Founded date: 2016
Investors 4
| Date | Name | Website |
| - | Sheatrust ... | sheatrustc... |
| - | S32 | s32.com |
| - | Section 32 | section32.... |
| - | Blue Ventu... | blueventur... |
Funding Rounds 5
| Date | Series | Amount | Investors |
| 10.09.2025 | Series C | $35.6M | S32 |
| 16.11.2023 | Grant | $10M | - |
| 28.07.2023 | Series B | $30M | - |
| 20.12.2020 | Series B | $32M | - |
| 12.07.2018 | Series A | $14M | - |
Mentions in press and media 20
| Date | Title | Description |
| 11.09.2025 | Octave Bioscience Secures Major Funding for Precision Neurology Advancement | Octave Bioscience secured $51.1 million in fresh capital. This includes a $35.6 million Series C equity round and a $15.5 million debt facility. Funds accelerate MSDA test commercialization. This blood-based diagnostic tool measures Multipl... |
| 10.09.2025 | Octave Bioscience: $35 Million Raised For Advancing Precision Care For Neurological Diseases | Octave Bioscience, a company focused on precision medicine for neurodegenerative conditions, has announced the successful close of a $35.6 million Series C equity financing round. In addition to this funding, the company has secured a $15.5... |
| 09.09.2025 | Octave Bioscience Closes $35.6M Series C | MENLO PARK, CA, Octave Bioscience has announced the close of its $35.6 million Series C equity financing round. >> Click here for more funding data on Octave Bioscience >> To export Octave Bioscience funding data to PDF and Exc... |
| 05.09.2025 | Octave Bioscience Raises $35M in Series C Financing | Octave Bioscience, a Menlo Park, CA-based commercial stage precision care company, announced the close of its $35.6M Series C equity financing and that it has entered into a $15.5M non-dilutive term loan agreement with Silicon Valley Bank (... |
| 16.11.2023 | Octave Bioscience Receives $10M Grant from The Michael J. Fox Foundation | Octave Bioscience, a Menlo Park, CA-based precision care company for managing multiple sclerosis and other neurodegenerative diseases, received a $10M Grant from The Michael J. Fox Foundation. The grant will be used for discovery, developme... |
| 28.07.2023 | California-based healthcare startup Octave Bioscience raises USD 30 million in Series B funding round | California’s MENLO PARK — –To provide a new standard of treatment for multiple sclerosis (MS) and other neurological illnesses, Octave Bioscience, a premier precision care firm, announced the conclusion of a USD 30M extension to its Series ... |
| 26.07.2023 | Octave Bioscience Raises $30M Series B Extension | MENLO PARK, CA, Octave Bioscience, a company focused on delivering a new standard of care for multiple sclerosis, announced a $30 million Series B Extension funding round. >> Click here for more funding data on Octave Bioscience &... |
| 26.07.2023 | Octave Bioscience Closes $30M Extension to Series B Funding | Octave Biosciences, a Menlo Park, CA-based commercial stage precision-medicine company, closed a $30M extension to its Series B funding. Backers included new investors Novartis (dRx Capital); Hikma Pharmaceuticals’ venture capital arm, Hikm... |
| 26.07.2023 | Octave Bioscience scores $30M for neurodegenerative disease offerings | Photo: Phil Boorman/Getty Images |
| 27.06.2023 | Nvidia backs Flywheel in $54M round to accelerate medical AI development | Join top executives in San Francisco on July 11-12, to hear how leaders are integrating and optimizing AI investments for success. Learn More Hours after teaming up with data cloud major Snowflake, Nvidia has backed a vendor working to over... |
Show more